

AHCCCS Fee-For-Service Effective January 1, 2004

Following is important information regarding changes to the AHCCCS Fee-For-Service pharmacy program administered by RxAmerica.

FORMULARY ADDITIONS:

OTC Prilosec Added as first line PPI therapy option.

FORMULARY DELETIONS/LIMITATIONS:

Prilosec (Rx)

Omeprazole (generic) Preferred product is OTC Prilosec.

PhosLo Capsule Capsule dosage form no longer available.

Patients must utilize tablet form.

Viagra Limited to 6 tablets per month.

Triptans Quantity limits enforced as 2 packages per

month.

Narcotic/acetaminophen

combination analysics All products limited to a maximum of 4 grams

acetaminophen per day.

STEP THERAPY/PRIOR AUTHORIZATION:

Leukotrine Inhibitors

(Singulair and Accolate) Restricted to Asthma use. Prior authorization

required for allergic rhinitis only after trial and

failure of standard therapy.

Renagel Restricted to use in hemodialysis patients who

have increased corrected serum calcium levels with trial and failure of traditional agents for use

in hyperphosphatemia.

Remicade Restricted for use in RA and severe Crohn's

disease after trial of conventional therapies.

Proton Pump Inhibitors

(Nexium, Protonix, Aciphex) Prior Authorization Required. Patient must have

tried OTC Prilosec as first line therapy option.

Statins Use Lovastatin, Lescol 80mg XL, Lipitor 10mg

and Altocor first line. All other Statin products require prior authorization with documented

need for increased cholesterol lowering.

Antiemetics All 5HT3 antagonists restricted to 6 tablets per

Rx based on National Guidelines.

Angiotensin Receptor Blockers Prior Authorization Required on all ARBs.

Restricted to use in patients who cannot tolerate at least 2 different ACE Inhibitors due to cough.

SSRI's Generic agents (Fluoxetine or Paroxetine) are

required first line therapy option for new SSRI utilizers. Patients who have currently stabilized on an antidepressant (not Generic) will remain

on alternate therapy option.

Tretinoin/Retin-A Prior Authorization required for patients over

age 24 and restricted for use in acne after other

agents have tried and failed.